Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 4, 2009, Pages 687-698

  Oefner, Christian ^a   Bandera, Monica ^a,b   Haldimann, Andreas ^a   Laue, Heike ^a,c   Schulz, Henk ^a   Mukhija, Seema ^a   Parisi, Sandro ^a   Weiss, Laurent ^a   Lociuro, Sergio ^a   Dale, Glenn E ^a  

^a Arpida Ltd   (Switzerland)

^b Firmenech SA   (Switzerland)

^c GIVAUDAN SCHWEIZ AG   (Switzerland)

Author keywords

DHFR; MRSA; Trimethoprim; X ray crystallography

Indexed keywords

DIHYDROFOLATE REDUCTASE; ICLAPRIM; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME INHIBITION; HYDROPHOBICITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; HYDROPHOBICITY; KINETICS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINES; STAPHYLOCOCCUS AUREUS; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETHOPRIM;

EID: 62549149036     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp024     Document Type: Article

References (51)

1. Kompis IM, Islam K, Then RL. DNA and RNA synthesis: Antifolates. Chem Rev 2005; 105: 593-620.
2. Then RL. Antimicrobial dihydrofolate reductase inhibitors - achievements and future options: Review. J Chemother 2004; 16: 3-12.
3. Hawser S, Lociuro S, Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 2006; 71: 941-8.
4. Schnell JR, Dyson HJ, Wright PE. Structure, dynamics and catalytic function of dihydrofolate reductase. Annu Rev Biophys Biomol Struct 2004; 33: 119-40.
5. Stone SR, Morrison JF. Mechanism of inhibition of dihydrofolate reductases from bacterial and vertebrate sources by various classes of folate analogues. Biochim Biophys Acta 1986; 869: 275-85.
6. Adra M, Lawrence KR. Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann Pharmacother 2004; 38: 338-41.
7. Grim SA, Rapp RP, Martin CA et al. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2005; 25: 253-64.
8. Ellis MW, Lewis JS. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis 2005; 18: 496-501.
9. Masters PA, O'Bryan TA, Zurlo J et al. Trimethoprim-sulfa-methoxazole revisited. Arch Intern Med 2003; 163: 402-10.
10. Moellering RC. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med 2006; 144: 368-70.
11. Howe RA, Spencer RC. Co-trimoxazole: Rationale for re-examining its indication for use. Drug Saf 1996; 14: 213-8.
12. Alanis AJ. Resistance to antibiotics: Are we in the post-antibiotic era? Arch Med Res 2005; 36: 697-705.
13. Saubolle MA. Antimicrobial resistance: Current status and future direction. Am J Rhinol 2006; 20: 667-71.
14. Schito GC. The importance of the development of antibiotic resistance in Staphylococcus aureus. Clin Microbiol Infect 2006; 12 Suppl 1: 3-8.
15. Linares J. The VISA/GISA problem: Therapeutic implications. Clin Microbiol Infect 2001; 7 Suppl 4: 8-15.
16. Brumfitt W, Hamilton-Miller JM, Wood A. Evidence for a slowing in trimethoprim resistance during 1981: A comparison with earlier years. J Antimicrob Chemother 1983; 11: 503-9.
17. Then RL, Kohl I, Burdeska A. Frequency and transferability of trimethoprim and sulfonamide resistance in methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. J Chemother 1992; 4: 67-71.
18. Tillotson G, Draghi D, Sahm D et al. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: Laboratory-based surveillance study. J Antimicrob Chemother 2008; 62: 109-15.
19. Dale GE, Langen H, Page MG et al. Cloning and characterization of a novel, plasmid-encoded trimethoprim-resistant dihydrofolate reductase from Staphylococcus haemolyticus MUR313. Antimicrob Agents Chemother 1995; 39: 1920-4.
20. Rouch DA, Messerotti LJ, Loo LS et al. Trimethoprim resistance transposon Tn4003 from Staphylococcus aureus encodes genes for a dihydrofolate reductase and thymidylate synthetase flanked by three copies of IS257. Mol Microbiol 1989; 3: 161-75.
21. Sekiguchi J, Tharavichitkul P, Miyoshi-Akiyama T et al. Cloning and characterization of a novel trimethoprim-resistant dihydrofolate reductase from a nosocomial isolate of Staphylococcus aureus CM.S2 (IMCJ1454). Antimicrob Agents Chemother 2005; 49: 3948-51.
22. Dale GE, Broger C, Hartman PG et al. Characterization of the gene for the chromosomal dihydrofolate reductase (DHFR) of Staphylococcus epidermidis ATCC 14990: The origin of the trimethoprim-resistant S1 DHFR from Staphylococcus aureus? J Bacteriol 1995; 177: 2965-70.
23. Dale GE, Broger C, D'Arcy A et al. A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance. J Mol Biol 1997; 266: 23-30.
24. Peppard WJ, Schuenke CD. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr Opin Invest Drugs 2008; 9: 210-25.
25. Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 2003; 13: 4217-21.
26. McPherson A. Preparation and Analysis of Protein Crystals. New York: John Wiley and Sons Inc., 1982.
27. Otwinowski Z. Oscillation data reduction program. In: Wawyey L, Isaacs N, Bailey S, eds. Proceedings of the CCP4 Study Weekend: Data Collection and Processing. Daresbury, UK: SERC Daresbury Laboratory, 1993; 56-62.
28. Collaborative Computational Project, Number 4. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994; 50: 760-3.
29. Gerber P. Peptide mechanics: A force field for peptides and proteins working with entire residues as smallest units. Biopolymers 1992; 32: 1003-17.
30. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997; 53: 240-55.
31. Engh R, Huber R. Accurate bond and angle parameters for X-ray protein refinement. Acta Crystallogr 1991; A47: 961-3.
32. Brünger AT. Free R value: A novel statistical quantity for assessing the accuracy of crystal structures. Nature 1992; 355: 472-5.
33. Laskowski RA, MacArthur MW, Moss DS et al. PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993; 26: 283-91.
34. Kraulis PJ. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 1991; 26: 946-50.
35. Merrit EA, Bacon DJ. Raster3D: Photorealistic molecular graphics. Methods Enzymol 1997; 277: 505-24.
36. Nicholls A, Honig B. GRASP: Graphical Representation and Analysis of Surface Properties. New York: Columbia University, 1992.
37. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
38. Landini P, Corti E, Goldstein BP. Mechanism of action of purpuromycin. Biochem J 1992; 284: 47-52.
39. Velazquez-Campoy A, Freire E. Isothermal titration calorimetry to determine association constants for high-affinity ligands. Nat Protoc 2006; 1: 186-91.
40. Roberts VA, Dauber-Osguthorpe P, Osguthorpe DJ et al. A comparison of the binding of the ligand trimethoprim to bacterial and vertebrate dihydrofolate reductase. Isr J Chem 1986; 2: 198-210.
41. Sharp KA, Nicholls A, Friedman R et al. Extracting hydrophobic free energies from experimental data: Relationship to protein folding and theoretical models. Biochemistry 1991; 30: 9686-97.
42. Koch AE, Burchall JJ. Reversal of the antimicrobial activity of trimethoprim by thymidine in commercially prepared media. Appl Microbiol 1971; 22: 812-7.
43. Hamilton-Miller JM, Stewart S. Trimethoprim resistance in enterococci: microbiological and biochemical aspects. Microbios 1988; 56: 45-55.
44. Miovic M, Pizer LI. Effect of trimethoprim on macromolecular synthesis in Escherichia coli. J Bacteriol 1971; 106: 856-62.
45. Saito H, Tomioka H, Ohkido S. Further studies on thymidine kinase: distribution pattern of the enzyme in bacteria. J Gen Microbiol 1985; 13: 3091-8.
46. Hamilton-Miller JM. Reversal of activity of trimethoprim against Gram-positive cocci by thymidine, thymine and 'folates'. J Antimicrob Chemother 1988; 22: 35-9.
47. Darrell JH, Garrod LP, Waterworth PM. Trimethoprim: Laboratory and clinical studies. J Clin Pathol 1968; 21: 202-9.
48. Hampele IC, D'Arcy A, Dale GE et al. Structure and function of the dihydropteroate synthase from Staphylococcus aureus. J Mol Biol 1997; 268: 21-30.
49. Laue H, Weiss L, Bernardi A et al. In vitro activity of the novel diaminopyrimidine iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. J Antimicrob Chemother 2007; 60: 1391-4.
50. Dale BA, Greenberg GR. Effect of the folic acid analogue, trimethoprim, on growth, macromolecular synthesis and incorporation of exogenous thymine in Escherichia coli. J Bacteriol 1972; 110: 905-16.
51. DeLano WL. The PyMOL User's Manual. San Carlos, CA, USA: DeLano Scientific, 2001.